Hepatic Vein Thrombosis (Budd‐Chiari Syndrome)

Willis C. Maddrey – 1 January 1984 – Hepatic vein thrombosis (Budd‐Chiari Syndrome) is a rare disorder resulting from obstruction to the outflow of blood from the liver. The characteristic pathologic findings are intense congestion most pronounced around the terminal hepatic venules, cell necrosis, and a scant inflammatory reaction. Major clinical manifestations include hepatomegaly, right upper quadrant abdominal pain, and ascites.

α–Antitrypsin Deficiency

Daniel Alagille – 1 January 1984 – Liver disease related to a–1–antitrypsin deficiency occurs only in Pi ZZ homozygous children. Eleven per cent of Pi ZZ infants present with prolonged neonatal cholestasis. In our group, 25 of 45 Pi ZZ infants with prolonged neonatal cholestasis presented with later cirrhosis. Persistence of jaundice beyond the sixth month of age, early development of splenomegaly, persistence of hard hepatomegaly and liver function abnormalities, and early portal fibrosis have a poor prognostic significance.

The Cambridge and King's College Hospital Experience of Liver Transplantation, 1968–1983

Keith Rolles, Roger Williams, James Neuberger, Roy Calne – 1 January 1984 – The postoperative course of 138 transplants performed in 137 patients in the Cambridge and King's College Hospital series between May 2, 1968 and April 1, 1983 is presented. During the last 15 years, criteria for selection of transplant candidates has been improved and types of disease categories, both suitable and unsuitable for liver transplantation, have been defined.

The Nature of IgG Complexes in Alcoholic Liver Disease

Phillip H. Stoltenberg, Ronald D. Soltis – 1 January 1984 – Circulating immune complexes have been described in most liver diseases, including alcoholic liver disease, although their pathogenic significance remains unclear. Currently available immune complex assays do not distinguish immunoglobulin aggregates from antigen‐antibody complexes. Immunoglobulin aggregate formation occurs in vitro at 37°C in the presence of hypergammaglobulinemia and/or hypoalbuminemia, conditions common in liver disease.

Immunosuppressive Serum Factors in Viral Hepatitis. III. Prognostic Relevance of Rosette Inhibitory Factor and Serum Inhibition Factor in Acute and Chronic Hepatitis

Wolfgang Grauer, Norbert W. Brattig, Hans Schomerus, Gerd FrÖSner, Peter A. Berg – 1 January 1984 – Two immunosuppressive serum factors, serum inhibition factor (SIF) and rosette inhibitory factor (RIF), were studied in sera from patients with acute and chronic viral hepatitis. In a study of 30 patients with acute viral hepatitis, an association was found between RIF, SIF, and biochemical and virological parameters in 27 patients (90%), 25 of whom recovered completely; two had a protracted course. In three patients, the clinical course was not reflected by the immunosuppressive factors.

An Assessment of Orthotopic Liver Transplantation in Acute Liver Failure

Roger Williams, A. E. S. Gimson – 1 January 1984 – Mortality of fulminant hepatic failure with standard supportive therapy is high (80 to 85%), but unfortunately most patients present to hospital already in Grade IV encephalopathy with severe liver dysfunction, and many have secondary organ damage. If seen earlier, during Grade III encephalopathy, recent experience with charcoal hemoperfusion can give good results (65% survival). Transplantation has a place in those patients who do not respond, and in cases with early Grade IV encephalopathy.

A New Method to Measure Portal and Hepatic Blood Flow Using Taurocholate in the Rat

Michèle Corbic, Didier Lebrec, Michele Le Dafniet, Serge Erlinger – 1 January 1984 – Hepatic artery and portal vein blood flows were assessed separately in anesthetized rats using radiolabeled taurocholate. The ratio of portal vein blood flow to total hepatic blood flow was calculated from measurements of taurocholate concentrations of portal vein, hepatic artery and hepatic vein, and of taurocholate hepatic extraction ratio. Animals were administered [14C]taurocholate intraperitoneally as a label of the taurocholate pool 24 hr before the experiments.

Subscribe to